Monopar Therapeutics (MNPR) Cash from Operations (2017 - 2020)
Historic Cash from Operations for Monopar Therapeutics (MNPR) over the last 4 years, with Q3 2020 value amounting to -$1.3 million.
- Monopar Therapeutics' Cash from Operations fell 11206.62% to -$1.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$4.1 million, marking a year-over-year decrease of 4260.87%. This contributed to the annual value of -$6.4 million for FY2024, which is 1850.47% up from last year.
- As of Q3 2020, Monopar Therapeutics' Cash from Operations stood at -$1.3 million, which was down 11206.62% from -$995474.0 recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Cash from Operations ranged from a high of -$305128.0 in Q2 2017 and a low of -$1.3 million during Q3 2020
- Moreover, its 4-year median value for Cash from Operations was -$752863.0 (2018), whereas its average is -$783147.5.
- Data for Monopar Therapeutics' Cash from Operations shows a peak YoY increase of 4982.04% (in 2018) and a maximum YoY decrease of 15967.43% (in 2018) over the last 5 years.
- Monopar Therapeutics' Cash from Operations (Quarter) stood at -$816021.0 in 2017, then soared by 36.37% to -$519212.0 in 2018, then fell by 28.79% to -$668705.0 in 2019, then crashed by 94.49% to -$1.3 million in 2020.
- Its last three reported values are -$1.3 million in Q3 2020, -$995474.0 for Q2 2020, and -$1.1 million during Q1 2020.